biOasis Technologies Ord Shs BIOAF

Primary Symbol: V.BTI.H

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > DNLI adds about C$375 million in market cap today

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Jun 20, 2023 1:17pm

208 Views

Post# 35505610

RE:DNLI adds about C$375 million in market cap today

Denali claims a neurofilament victory in Hunter syndrome, two years after letting down Wall Street

Max Gelman

Senior Editor

Denali Therapeutics once again touted biomarker data for its experimental Hunter syndrome drug Tuesday morning, aiming to push the program toward FDA approval after disappointing Wall Street two years ago

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario